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SUMMARY 
 
Background: Involvement of small airways has been hypothesized to be 
responsible of poor asthma control in subgroups of patients, also due to the 
difficulty of inhaled drugs to reach peripheral airways. 
Aim: To evaluate in a sample of moderate-severe asthmatic patients under 
treatment with inhaled corticosteroid/long acting beta2-agonist (ICS/LABA) 
combinations, the relationship between asthma control, as assessed by 
traditional clinical, functional and biological findings, and some measurements 
of small airway involvement. 
Patients and methods: 31 asthmatic patients regularly treated with ICS/LABA 
combinations were evaluated for the level of asthma control according to GINA 
guidelines, by a 4-month period of diary card and peak expiratory flow (PEF) 
monitoring, FEV1 and exacerbation rate; sputum eosinophils and fractional 
exhaled nitric oxide (eNO50) were also measured. Small airway involvement 
was assessed by single breath nitrogen washout (CV, ΔN2%), alveolo-arterial 
O2 and arterial-alveolar CO2 gradients (AaDO2, aADCO2), and alveolar 
concentration of nitric oxide (CalvNO). 
Results: According to GINA guidelines, patients were defined as well controlled 
(N=10), partly controlled (N=11) and not controlled (N=10). No significant 
difference was observed among the groups as regards markers of small airway 
involvement, as well as for biomarkers. When well controlled and partly 
controlled were considered together, not controlled patients showed a 
significantly higher AaDO2 difference. A significant correlation was observed 
between AaDO2 and FEV1 %pred, sputum eosinophil percentage, and rescue 
medication use. 
Conclusions: Small airway involvement as assessed by AaDO2 may be 
observed in clinically not controlled moderate-severe asthmatics under 
ICS/LABA combination treatment, despite a not significant difference in FEV1 





eNO Exhaled nitric oxide 
CalNO Alveolar concentration of nitric oxide 
JawNO Bronchial production of nitric oxide 
FEV1 Forced expiratory volume in 1 second 
AaDO2 Alveolar-arterial difference in oxygen 
aADO2 Arterial-alveolar difference in carbon dioxide 
PEF Peak expiratory flow 
VC Vital capacity 
TLC Total lung capacity 
RV Residual volume 
  ΔN2 L-1 Slope of the nitrogen alveolar plateau (phase III) 
CV Closing volume 
CV/VC Closing volume as percentage of vital capacity 
PaO2 Partial tension of oxygen 
PaCO2 Partial tension of carbon dioxide 
PAO2 Medium alveolar pressure of oxygen 
PACO2 Medium alveolar pressure of carbon dioxide 
Vd/Vt Physiologic deadspace ventilation  
ICS Inhaled corticosteroids 
LABA Long acting beta2-agonists 
 INTRODUCTION 
 
Asthma is a chronic airway disease characterized by episodic symptoms 
that are associated with functional alterations. It is well known that airways 
inflammation plays a basic role in the pathogenesis of asthma, and many 
autoptic and bioptic studies have shown that inflammation involves the entire 
bronchial tree, from proximal to distal airways (1,2).  Many studies have 
demonstrated that inflammatory cells, particularly eosinophils, are well 
represented in both the inner and the outer layer of the small airway walls, 
sometimes with a higher density in comparison with large airway walls (3,4). 
Small airways are the most peripheral airways with an internal diameter < 2 mm 
and in this zone oxygen and carbon dioxide exchanges take place. The 
contribution of small airways to the development of the clinical features and 
functional impairment in asthma is incompletely understood, probably due to the 
unavailability of definite non invasive techniques for the study of small airways. 
Pathological changes in the small airways can be detected by physiological 
tests. Among these, the single breath nitrogen washout test (SbN2) can be used 
to evaluate the presence of uneven ventilation. In asthma, In’t Venn showed 
that airway closure as measured by the single breath nitrogen test, with 
evaluation of the slope of the phase III and of the closing volume, can 
discriminate between severe asthmatic patients with and without recurrent 
exacerbations during clinically stable episodes (5). This abnormal distribution of 
alveolar ventilation may result in a ventilation-perfusion (V/Q) ratio imbalance, 
determining pulmonary gas-exchange abnormalities that may reflect changes in 
the small airways (6,7). It was demonstrated that bronchoconstriction induced 
by methacoline (with a direct mechanism on smooth muscular cells) or by 
adenosine-5-monophosphate (with an indirect mechanism determining an 
inflammatory process) induces pulmonary gas exchange abnormalities as 
assessed by V/Q ratio (8). Interestingly, after inhaled salbutamol, which acts 
mainly on proximal airways, these disturbances persisted. Other indices of 
abnormal distribution of ventilation (like those derived from multiple-breath 
nitrogen washout technique or impulse oscillometry) have been used to assess 
small airway involvement (9-11), with some positive results in terms of either a 
distinction between symptomatic vs non symptomatic patients or a correlation 
 with other functional or inflammatory markers of airway involvement. 
Some biomarkers have been studied to detect small airway inflammation 
in asthma (12). Fractional exhaled nitric oxide (eNO50) is currently the most 
widely used biomarker in the exhaled breath and it is often increased in asthma, 
even in mild and asymptomatic condition (13). This measure can be done also 
at different expiratory flows resulting, by a mathematical model, in a measure of 
alveolar nitric oxide concentration (CalvNO) and bronchial nitric oxide flux 
(JawNO) (14). CalvNO has been considered as a marker of eosinophilic 
inflammation involving small airways (15), and some papers have shown that 
this measurement, but not eNO50, may distinguish controlled from uncontrolled 
asthmatics (16, 17). 
It is known that there are asthmatics with the same level of functional 
impairment of large airways as assessed by FEV1, but with different clinical 
control of disease, in terms of symptoms and exacerbations. Among the many 
possible explanations, it has been postulated that this different asthma control 
might be due to a different involvement of the peripheral airways. However, it is 
not clear if the pathology of small airways represents a different phenotype of 
asthma or if it represents just a marker of greater severity of the disease. 
According to this background, we postulated that small airways 
dysfunction, as assessed by some functional and biological findings, may 
distinguish asthmatic patients with different levels of asthma control. In this 
attempt, we selected a homogeneous group of patients under regular treatment, 
and we compared markers of involvement of large (FEV1, sputum eosinophils) 
and small airways (single-breath test, alveolar-arterial differences of oxygen 
and carbon dioxide, eNO) between patients with controlled and uncontrolled 
asthma as assessed by GINA guidelines (18,19). Our hypothesis was that 
markers of small airway involvement may distinguish better than markers of 







 PATIENTS AND METHODS 
 
Study population 
Thirty-one patients (13 males, age: 55.9±10.7 yrs) were studied. All 
patients have been followed in our clinic since 1 year at least, and the diagnosis 
of asthma had been previously performed according to GINA guidelines in 
presence of typical symptoms and risk factors, and the demonstration of 
reversible airway obstruction and/or bronchial hyperresponsiveness (19). All 
patients had skin prick test performed to assess the presence of atopy, which 
was defined as a positive response (mean wheal diameter ≥ 5 mm) to at least 
one of the 11 common inhalants. 
Patients were selected from our clinic routine according to the following 
criteria: a) male or female, never smoker or ex-smoker with less than 10 pack-
years; b) regular treatment with GINA step 3 or step 4 level of therapy (medium-
high doses of inhaled steroids and long acting beta-2-agonists) and a good 
level of compliance to treatment (as evaluated by the physician); c) a post-
bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 60% pred. To be 
included in the study, they needed to be clinically stable, without history of 
recent (< 4 weeks) exacerbations, and to have signed an informed consent.  
Exclusion criteria included the frequent use of oral corticosteroids, severe 
comorbidities, or an history of brittle asthma. The study had been notified to the 
Local Ethic Committee. 
 
Study design 
The study took place in two days. In the first visit, all inclusion and 
exclusion criteria were checked and patients were asked to participate to the 
study. In the second visit, four weeks apart, each subject underwent, in the 
following: a) traditional standard pulmonary function tests, including expiratory 
flow/volume curves, static lung volumes by body pletismography, carbon 
monoxide diffusing capacity, and SBN2; b) resting alveolar-arterial and arterial-
alveolar differences of respiratory gases (AaDO2 and aADCO2); c) 
measurement of biomarkers of airway inflammation (eNO and eosinophil 
percentages in sputum induction). All measurements were performed in the 
morning (between 8:30 to 12 am), after the patients had taken their regular 
 drugs in the early morning. 
During the four weeks between visit 1 and visit 2, patients monitored 
daytime and nighttime symptoms and rescue medication use, and measured 
Peak Expiratory Flow (PEF) by Mini-Wright Peak Flow Meter (Clement Clarke 
International Limited, Edimburgh Way, Essex, CM20 2TT, UK) in the morning 
and in the evening, reporting these data on a diary card. At the second visit, 
asthma control was assessed, by taking in consideration the frequency of 
symptoms and rescue medication use, limitation in daily life, FEV1 and the rate 
of exacerbations in the last year. According to GINA Guidelines (12), patients 
were considered well controlled if they reported occasional symptoms and use 
of rescue medication (less than 2 times a week) as assessed by diary card of 
the previous 4 weeks, no limitation in daily life, FEV1 (in % of the best as 
assessed on the FEV1 measurements obtained in the year before the current 
study), no exacerbation in the last year and a PEF variability (as expressed by 
the mean value over 4 weeks of daily maximal amplitude: highest – 
lowest/mean) < 20%. Patients were defined as partly controlled if they did not 
satisfy to one or two of the previous criteria, while they were defined 
uncontrolled if three or more of the previous criteria were not satisfied. Patients 
were excluded from the study if they had presented an acute asthma 
exacerbation during the 4-week monitoring period. 
 
Methods 
Pulmonary function tests were obtained by a Medical Graphics Elite 
Series Tm Pletismograph (St. Paul, Minnesota, USA). The measurement of the 
flow/volume curves, static lung volumes and diffusing capacity were performed 
according to the acceptability and reproducibility criteria of ERS/ATS guidelines 
(20). SbN2 test was performed with the same apparatus (21). During this test 
each patient performed a slow full inspiratory and expiratory vital capacity (VC) 
maneuver at flow rate of 0.5 L/sec while inhaling pure oxygen. The expiratory 
nitrogen concentration (%N2) was plotted against lung volume (between total 
lung capacity, TLC, and residual volume, RV), producing the expiratory nitrogen 
washout curve (21, 22). The slope of the nitrogen alveolar plateau (ΔN2) was 
calculated by drawing the best fit line through phase III of expiratory 
volume/concentration curve (21). The first departure from this straight line 
 indicates the closing volume (CV), expressed as the ratio of VC (CV/VC). Both 
ΔN2 and CV/VC were directly calculated by the computer program and checked 
by the same investigator, which might change the value if appropriate. The 
measurements were accepted only if VC during the single breath N2 test was 
within 10% of the VC measured at spirometry. 
A computer program to measure breath by breath alveolar pressure 
(PA), alveolo-arterial O2 gradient (AaDO2) and arterial-alveolar CO2 gradient 
(aADCO2) by a mass-spectrometer (MSX of Collins-Morgan-Ferraris, Pisa, Italy) 
was implemented. 
This technique allows to assess the AaDO2 and aADCO2 by measuring 
simultaneously the partial tensions of oxygen (PaO2) and carbon dioxide 
(PaCO2) in the arterial blood (by arterial blood gas analysis) and their medium 
alveolar pressure (PAO2 and PACO2), breath by breath, when the 
instantaneous respiratory quotient equals the average within each tidal volume 
(Rahn's definition). In addition, analysis of arterial tension of CO2 and its 
average expiratory pressure can estimate the physiological dead space (vd), 
expressed as the ratio of tidal volume (Vd/Vt), index of effective ventilation for 
gas exchange using Enghoff equation (PaCO2-PECO2/PaCO2) (23, 24). 
Fractional eNO was measured in real time by NOA Sievers analyzer 
(NOA 280; Sievers, Boulder, CO, USA) on a single breath of 10 seconds 
against a resistance that results in an expiratory flow of 50 ml/sec (eNO50). The 
mean value of at least two acceptable measures on the alveolar plateau of the 
nitric oxide (NO) concentration curve was considered. This method is well 
standardized and this value expresses the production of NO by lower airways 
(25). Fractional NO production was also computed using the mathematical 
model that allows analysis of the NO concentration measured at the mouth with 
a similar procedure, but obtained from different expiratory flows (50, 100 and 
200 ml/sec, using different expiratory resistances). This technique allows to 
measure the NO concentration derived from the bronchioloalveolar district 
(CalvNO) and the NO production from the large and medium airways (JawNO) 
(14). 
 Sputum was induced according to the method previously described (26) 
using salbutamol pretreatment, hypertonic saline (NaCl, 4.5%) nebulized with 
an ultrasonic nebulizer (Ultraneb 2000, DeVilbiss, Somerset, Pa., USA) for 5-
 minute periods for up to 15 minutes, and FEV1 measurement before and every 
5 minutes. Inhalation was stopped in presence of symptoms of  
bronchoconstriction, or excessive FEV1 decline(> 30% from baseline). The 
whole sputum sample was diluted with an equal volume of 0.1% dithiotreithol 
(Sputasol; Unipath Ltd, Basingstoke, UK). Samples were treated as previously 
reported (27) At least 300 non-squamous cells were counted. Macrophage, 
lymphocyte, neutrophil, eosinophil percentages were expressed as percent of 
total inflammatory cells, excluding squamous cells. The upper limit of normal 
range for sputum eosinophils was set at 2%, as measured in a group of normal 
subjects (28).  
Furthermore, we presumed that in these patients with abnormal markers 
of small airway involvement, the addition of montelukast, an oral anti-
inflammatory agent  which may easily reach the small airways by the systemic 
administration, might modify these abnormalities.  In this attempt, we added oral 
montelukast to the current inhaled therapy for one month and then we repeated 
all baseline measurements (see attachment A). 
In addition, it is possible that alterations of small airways can cause flow 
limitation at rest. For this reason, in a subgroup of patients, the measurement of 
flow limitation, by Hyatt technique, using dedicated software, was performed 
(see attachment B).  
 
Statistical analysis 
Due to the exploratory nature of the study, no formal sample size 
calculation was made. 
Patients were divided into “well controlled”, “partly controlled” and “not 
controlled” according to GINA Guidelines, after taking in consideration clinical 
and functional data as previously reported. 
Data are expressed as mean (± standard deviation) or median (range) for 
normally and non normally distributed parameters. The comparison between 
controlled and non controlled patients were performed by one-way ANOVA 
comparison or by Mann-Withney or Kruskall Wallis tests for normally and non 
normally distributed parameters, respectively, and correlations between two 
variables by Pearson or Spearman tests respectively. A level of probability 
lower than 0.05 was considered as statistically significant. 
 RESULTS 
 
 Thirty-two patients were enrolled in the study. One of them was not 
included due to the occurrence of asthma exacerbation during the monitoring 
period, requiring a short course of oral corticosteroids. The main clinical and 
functional data of the 31 patients examined are reported in Table 1. In the last 6 
months, all patients were under regular treatment with inhaled corticosteroids 
(ICS: budesonide, 1600 mcg daily in 13 patients, fluticasone propionate 1000 
mcg daily in 18 patients) associated with long-acting beta2-agonists (LABA). No 
patients had used montelukast or regular low-dose oral corticosteroids or anti-
IgE treatment. They represented a sample of moderate-severe asthmatic 
patients, with mean FEV1 in the normal range: although 13 of them had a FEV1 
value < 80%pred, it was however > 80% of their best value measured in the 
previous years. Static lung volumes and diffusion lung capacity were normal. 
 At the second visit, after the 4-week monitoring period, the control of 
asthma was assessed according to that previously reported (see methods). 
FEV1 value measured at this visit was compared with the best FEV1 obtained 
by the patient in the visits performed in our Unit in the previous years. 
According to GINA guidelines, patients were divided in: well controlled (N=10), 
partly controlled (N=11) and not controlled (N= 10). Table 2 shows the single 
values which contributed to the definition of the asthma control. Patients with 
partly controlled asthma were different from well controlled patients only for a 
higher number of asthma exacerbations in the previous year; in contrast 
patients with not controlled asthma differed from well controlled and/or partly 
controlled patients with respect to almost all findings which contributed to the 
evaluation of the asthma control, apart from FEV1. 
 Sputum eosinophil percentage and fractional exhaled nitric oxide 
concentration in exhaled breath (eNO50) were not different among the different 
categories of asthma control, both when three categories were considered 
separately (Figure 1) and when well controlled and partly controlled were 
considered together in comparison with not controlled patients. No difference 
among groups with different asthma control was observed for sputum neutrophil 
percentages (52.2[10.7-70.7]% vs 46.8[3.8-95.9]% vs 52.3[1.4-88.8]% in well 
controlled, partly controlled and not controlled patients, respectively. 
  Markers of small airway involvement were not significantly different in the 
three categories of asthma control (Table 3). However, when we included 
patients with well controlled and partly controlled asthma in a same category of 
“controlled asthma”, we observed that not controlled patients showed a higher 
alveolar-arterial O2 difference than not controlled patients (Table 4). No 
significant difference was still observed between these two categories as 
regards other markers of small airway involvement (mid-expiratory flow, single 
breath analysis, eNO). 
 Among markers of small airway involvement, alveolar-arterial O2 
difference significantly correlated with FEV1 %pred (r=-0.49, p<0.05), weekly 
beta2use (r=0.42, p<0.05) and sputum eosinophil percentage (r=0.66, p<0.05) 
(Figure 2), while arterial-alveolar CO2 difference correlated with FEV1 %pred 
(r=-0.40, p<0.05) and with PEF maximal amplitude (r=0.44, p<0.05). The slope 
of the nitrogen alveolar plateau significantly correlated only with FEV1 %pred 
(r=-0.42, p<0.05). 
 When patients were divided in two groups according to the normal value 
of the three markers of small airway involvement (ΔN2: < 1.5 %N2L-1, AaDO2: < 
18 mmHg, and CalvNO: < 5 ppb), patients with abnormal AaDO2 had a 
significantly higher rescue beta2 use  (1.6±2.1 vs 0.3±0.7, p<0.05) and sputum 
eosinophil percentages (15.1[0-70] vs 2.6[0-13], p<0.05) compared with 
patients with normal AaDO2. No difference was found between patients with the 
normal and abnormal values of  ΔN2 and CalvNO. 
 There was no significant correlation between different markers of small 
airways involvement (ΔN2, AaDO2, CalvNO). 
 There was no significant difference between atopic and nonatopic 
patients for clinical and functional findings, including small airways involvement, 
except for a higher level of asthma severity in atopic subjects, as expressed by 
a higher rescue beta2-agonist use and a poorer level of control in atopic 








 Our exploratory study shows that the measurement of the alveolar-
arterial oxygen difference (AaDO2) may distinguish patients with uncontrolled 
asthma from patients with well controlled or partly controlled asthma, despite 
they did not demonstrate a significant difference in FEV1 and other markers of 
large airway inflammation (like sputum eosinophil percentage and eNO50). 
Because AaDO2 is an indirect measurement of the ventilation/perfusion (V/Q) 
inequality related to an heterogeneous peripheral distribution of the alveolar 
ventilation, this finding supports the hypothesis that involvement of small 
airways is associated with poor asthma control. 
 Small airway dysfunction in asthma is well known to marginally contribute 
to the total airway resistance, while it strongly influences the peripheral 
distribution of the ventilation and the efficiency of the gas exchange. The 
evaluations of the alveolar-arterial and arterial-alveolar gradients of oxygen and 
carbon dioxide has been used several years ago to detect and quantify the 
abnormal V/Q ratio in patients with asthma or chronic obstructive pulmonary 
disease (COPD) showing that these measurements were frequently abnormal 
despite mildly reduced or normal FEV1 values (6, 29). Only few authors have 
evaluated the sensitivity of AaDO2 in detecting functional abnormalities in gas 
exchange, in comparison with other methods commonly used for studying the 
abnormalities in the ventilation/perfusion ratio (8,30); in these cases, AaDO2 
significantly increased after bronchial challenge also in presence of mild non 
significant reduction in FEV1. It is commonly believed that in airway diseases 
alveolar gradients of oxygen and carbon monoxide may be representative of the 
abnormal distribution of the convective ventilation due to some heterogeneity in 
the small airway involvement. We used a well validated method (23) for the 
assessment of gas exchange by automated analysis of O2 and CO2 alveolar to 
arterial differences according to Rahn’s definition. Contrary to the end-tidal 
values of gas concentration, this automatic technique allows a more precise 
determination of both extremes of the asynchronous emptying of the lung units, 
because the contribution of both low (shunt effect) and high (wasted ventilation) 
V/Q mismatch is considered (24). The importance of this technique, in 
comparison with the end-tidal method, has been demonstrated by Wagner (31) 
 in COPD patients using the multiple inert gas technique in terms of a better 
accuracy. 
 To our knowledge, this is the first study which used this specific 
measurement of V/Q inequality as a test of involvement of small airways in 
asthma, showing an association with poor asthma control. Many studies have 
assessed the inequality of distribution of ventilation in asthmatic patients, using 
different methods (single and multiple-washout nitrogen test, lung imaging, 
impulse oscillometry); in general these studies showed a relationship between 
these indices and the level of severity or control of asthma (10, 32) and an 
improvement in these indices after treatment with inhaled ICS or ICS/LABA 
combinations with the potential of reaching the lower airways (33). According to 
our data, we suggest that the measurement of the alveolar-arterial gradients of 
oxygen and carbon dioxide may represent a new test for the assessment of 
small airways involvement in asthma, maybe more sensitive than other 
traditional measurements. 
 Differently from other studies which examined patients with large variety 
of asthma severity and asthma treatment (from mild intermittent to severe 
persistent asthmatics, from untreated to regularly treated asthmatics with 
different level of asthma therapy) (10, 17), we selected a fairly homogeneous 
population with moderate-to-severe asthma, regularly treated with medium-high 
dose of ICS/LABA combinations but with different level of asthma control as 
assessed according to GINA guidelines. Furthermore, the evaluation of control 
was based on the accurate recording of symptoms, rescue medication use and 
PEF variability measured during a 4-week period immediately before the 
functional evaluation. Interestingly, the level of control was related neither to a 
different FEV1 in %pred, which showed a mild not significant difference among 
the three groups of asthma control, nor to a different level of markers of large 
airway inflammation (like sputum eosinophil percentage and eNO50). Although 
there is still some uncertainty on which part of the airways sputum eosinophil 
and fractional eNO50 come from, there is large consensus that these 
measurements are mainly expression of the inflammation of the more proximal 
airways (34). The possibility to distinguish controlled from not controlled 
asthmatic patients according to AaDO2 and not to FEV1, sputum eosinophils 
and eNO50 suggests that small airway involvement may be another independent 
 factor contributing to a poorer asthma control. 
 Despite the lack of difference in sputum eosinophil percentage among 
patients with different level of asthma control, there was a significant correlation 
between AaDO2 and sputum eosinophil percentage. This observation might be 
explained by the hypothesis that sputum eosinophil in larger airways (as 
assessed by the standard sputum induction procedure) may be associated with 
a higher level of eosinophilic inflammation also in the small airways, as it has 
been suggested by some morphologic studies (4), and then that this greater 
inflammatory involvement of the lower airways may influence the V/Q lung 
distribution as assessed by AaDO2. In alternative, sputum samples obtained 
during the induction procedure may include secretions coming from both the 
large and the small airways (particularly the samples collected at the end of the 
induction procedure), then representing the inflammatory profile of both large 
and small airways. 
 We did not find any significant difference among categories of asthma 
control as regards single-breath nitrogen washout indices and fractional NO. 
This is in contrast with previous observations, which however included patients 
with a larger variety of asthma severity (from mild untreated to severe treated 
asthmatics) (16) or greater number of patients (35). This fact might be explained 
by a greater inter-patient variability in the measurement of ΔN2 and CalvNO in 
comparison with AaDO2, therefore allowing to obtain a significant difference 
between small samples of patients included in the different asthma categories 
with a more reproducible test than with other less reproducible tests. 
 Our study has some limitations. Firstly, the number of patients studied is 
relatively small and due to the exploratory characteristic of this study, a formal 
power calculation was not performed. However, we selected a fairly 
homogeneous group of moderate-severe asthmatic patients, in order to reduce 
the influence of asthma severity and level of anti-asthma treatment. 
Furthermore, other previous studies included a similar number of asthmatic 
patients (32, 36). Secondly, we did not use other putative markers of small 
airway involvement, like impulse oscillometry or lung imaging. However, we 
compared the new marker (AaDO2) with the two more frequently used tests 
(ΔN2 and CalvNO) for studying small airways. Finally, a control group was not 
included in this study, although we have data in normal subjects and mild 
 asthmatics showing a clear distinction with the sample studied. 
 In conclusion, our study suggests that V/Q inequality of peripheral lung 
as measured by AaDO2 may be a marker of small airway involvement in 
moderate-severe asthmatics using treatment with ICS and LABA, and that this 
measurement may be associated with a different level of asthma control better 
than more traditional markers of large airway involvement. 
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Legend of the figures 
 
Figure 1. Box-plot of sputum eosinophil percentage and exhaled Nitric Oxide in 
controlled, partly controlled and non controlled patients. 
 
 
C=controlled; PC= partly controlled; NC= not controlled; Eosinophils %= sputum 
eosinophils percentage; eNO= exhaled nitric oxide  
 Figure 2. Correlation between alveolar-arterial difference of oxygen and FEV1 (% 




AaDO2= alveolar-arterial difference in oxygen, FEV1%= forced expiratory volume in the 
first second; Eosinophils %= sputum eosinophil percentage.  
 Table 1. Clinical and functional characteristics of the examined patients 
Number 31 
Gender (male:female) 13:18 
Smoke (never:ex) 24:7 
Atopy (atopic:nonatopic) 10:21 
Age, yrs (M±SD) 55.9±10.7 
FEV1, L (M±SD) 2.35±0.8 
FEV1, % pred (M±SD) 87.2±19.0 
FEV1, % best 92.0±7.0  
FEF25-75, L/sec (M±SD) 1.54±0.9 
FEF25-75, % (M±SD) 45.6±22.9 
TLC, L (M±SD) 6.09±1.34 
TLC, % pred (M±SD) 109.6±12.0 
DLCO ml/min/mmHg (M±SD) 25.9±8.2 
DLCO, % pred (M±SD) 101.5±17.5 
Sputum eosinophils, % 8.5(0.0 – 7.0) 
Sputum neutrophils, % 48.8 (1.4 – 95.9) 
M= mean; SD= standard deviation; FEV1= forced expiratory volume in the first second; 
FEF25-75= forced expiratory flow between 25 and 75% of forced vital capacity; TLC= 
total lung capacity; DLCO= lung diffusion of carbon monoxide 
 
 
 Table 2. Level of control defined at the second visit, according to GINA guidelines, in 
the 31 examined patients 
  Well controlled Partly controlled Not controlled  
N° 10 11 10 
FEV1 % pred (M±SD) 89.6 ± 18.7 87.5 ± 24.6 82.7±16.3 
Symptoms/week (M±SD) 0.3 ± 0.6 1.7 ±  2.1 10.6 ± 10.4* 
PEF-MA % (M±SD) 13.4 ± 7.2 22.0 ± 9.4 22.4 ± 7.6 ** 
beta2-use/week (median) 0.0 (0.0 - 2.0) 0.0 (0.0 – 2.0) 2.0 (1.5 - 7.0)* 
Exacerbations (median) 0.0 (0.0 – 1.0)  1.0 (0.0 – 2.0) ** 1.0 (1.0 – 3.0)** 
M= mean; SD= standard deviation; FEV1= forced expiratory volume in the first second; 
PEF-MA= daily maximal amplitude of Peak Expiratory Flow 
*p<0.05 vs well controlled and partly controlled;  ** p<0.05 vs well controlled 
§ p<0.05 vs well controlled 
 
 
Table 3. Comparison of the markers of small airway involvement between controlled, 
partly controlled and not controlled asthmatic patients.  
  Well controlled Partly controlled Not controlled 
Number 10 11 10 
FEF25-75 % pred (M±SD) 48.4 ± 19.4 49.4 ± 28.9 38.9 ±19.1 
CV/VC % (median) 0.0(0.0 – 10.6) 0.0(0.0 – 25.0) 0.0(0.0 – 17.6) 
ΔN2%L-1 (median) 2.7(0.9 – 7.7) 2.2 (1.1 – 6.5) 2.5(0.9 – 4.8) 
CalvNO ppb (M±SD) 6.65 ± 5.3 12.9 ± 4.8 6.28 ± 4.3  
AaDO2 mmHg (M±SD) 23.1 ± 8.2  21.5 ± 11.9  30.3 ± 10.1  
aADCO2 mmHg (M±SD)  1.0 ± 2.5  2.72 ± 3.5  3.4 ± 3.1 
 M= mean; SD= standard deviation; FEF25-75= forced expiratory flow between 25 and 
75% of forced vital capacity; ΔN2= the slope of the phase III obtained by the single 
breath nitrogen washout; CV= closing volume; VC= vital capacity; CalvNO= alveolar 
concentration of eNO; A-aDO2 and a-ADCO2= alveolar-arterial and arterial-alveolar 
differences in oxygen and carbon dioxide. 
 Table 4. Comparison of the markers of small airway involvement between controlled 
(well controlled and partly controlled) and not controlled patients 
  Controlled Not Controlled 
Number 21 10 
FEF25-75 % pred (M±SD) 49.0 ± 24.4 38.9 ± 19.1 
CV/VC % (median) 0.0 (0.0-25.0) 0.0 (0.0-17.6) 
ΔN2%L-1 (median) 2.3 (0.9 - 7.7) 2.5 (0.9 - 4.8) 
CalvNO ppb (M±SD) 9.9 ± 5.8 6.2 ± 8 4.3 
JawNO ml/sec-1 (M±SD) 37.4 ± 78.7 58.3 ± 92.5 
AaDO2 mmHg (M±SD) 22.3 ± 0.1 30.3 ± 10.1* 
aADCO2 mmHg (mean±SD) 1.9 ± 3.1 3.4 ± 3.1 
M= mean; SD= standard deviation; FEF25-75= forced expiratory flow between 25 and 
75% of forced vital capacity; ΔN2= the slope of the phase III obtained by the single 
breath nitrogen washout; CV= closing volume; VC= vital capacity; CalvNO= alveolar 
concentration of eNO; JawNO= bronchial production of eNO; A-aDO2 and a-ADCO2= 























Twenty four of the 31 patients who completed the baseline evaluation 
accepted to add oral montelukast to the current therapy and to repeat all 
measurements after one month. After montelukast, no significant change in 
symptoms, rescue medication use, daily PEF variability, FEV1 (from 83.2±19.7 
to 84.1±18.8 %pred, n.s.), and sputum eosinophils percentage (from 1.2 (0.3-
70.0) to 12.8 (0.0-73.0) %,n.s.) was observed in comparison with the baseline 
evaluation, in all 24 patients. When indices of small airways involvement were 
considered (Table), no significant change was still observed. The selection of 
the 7 patients out of 24 who resulted not controlled at the baseline evaluation 
showed a trend to improve FEV1 (from 79.4±14.4 to 85.1±18.4 %pred, p=0.09) 
and fractional eNO (from 35.4±32.8 to 24.3±21.7 ppb, p=0.07) and a significant 
reduction in AaDO2 (from 32.1±7.9 to 25.87±.7 mmHg, p=0.034).  
The addition of oral montelukast did not induce any significant 
improvement in the clinical, functional and biological findings, as well as in 
indices of small airway involvement. Our hypothesis was that the oral 
administration might allow to reach small airways and then improve at this level 
the inflammatory process, as suggested by previous papers (1). Also in this 
case, the exploratory characteristic of this study does not allow to draw any 
conclusion from this part of the study. In particular, only not controlled patients 
showed a significant improvement of AaDO2: this group was numerically very 
small and there was no control group. Furthermore, the duration of montelukast 
treatment might be too short for demonstrate a positive effect, as some studies 
suggest that a longer duration of treatment is needed for obtaining a consistent 
anti-inflammatory effect. Therefore, no conclusion can be drawn from this part 
of the study, although the mild improvement in AaDO2 observed in not 
controlled asthmatics might require to be assessed in larger groups of patients 







1) Zelder MR, Kleerup EC, Goldin JG, et al. Montelukast improves regional air-



































 Table. Mean values of FEV1, sputum eosinophil percentages and indices of small 
airway involvement, before and one month after the addition of oral montelukast to the 
current therapy, in 24 asthmatic patients 
  Pre-montelukast Post-montelukast 
FEV1 % (M±SD) 83.2±19.7 84.1±18.8 
FEF25-75 % pred (M ± SD) 38.1±16.9 40.2±14.9 
CV/VC % (median) 0.0(0.0 – 25.0) 0.0(0.0 – 23.4) 
ΔN2 % L-1 (median) 2.3(0.9 – 7.7) 2.4(0.9 – 4.8) 
eNO50 ppb (M ± SD) 28.6±19.5 26.8±19.7 
CalvNO ppb (M±SD)  9.1±6.0 10.8±8.1 
PBrNO nl/sec-1(M±SD) 23.9±60.6 31.7±80.8 
Sputum eosinophils % 
(median) 
12.2(0.3 – 70.0) 12.8(0.0 – 73.0) 
AaDO2 mmHg (M±SD) 26.6±9.3 25.1±7.7 
aADCO2 mmHg (M±SD) 2.63±2.8 2.45±2.9 
PaO2 mmHg (M±SD) 84.0±9.2 84.8±8.1 
 Symptoms/Week (M±SD) 2.8±4.2 2.1±4.4 
PEF-MA (M±SD) 20.2±8.7 16.9±11.1 
beta2-use/week (median) 0.0(0.0 – 5.0) 0.0(0.0 – 3.0) 
M= mean; SD= standard deviation; FEV1= forced expiratory flow in the first second; 
FEF25-75= forced expiratory flow between 25 and 75% of forced vital capacity; CV= 
closing volume; VC= vital capacity; ΔN2= the slope of the phase III obtained by the 
single breath nitrogen washout; eNO= exhaled nitric oxide; CalvNO= alveolar 
concentration of eNO; JawNO=bronchial production of eNO; Eo%= sputum eosinophil 
percentage; A-aDO2 and a-ADCO2= alveolar-arterial and arterial-alveolar differences in 
oxygen and carbon dioxide; PAO2= partial pressure of oxygen; PEF-MA= daily 









 Attachment  B 
Ancillary Project 
Flow-limitation (FL) at rest is a condition in which there is a reduction of 
expiratory flow reserve, whereby the subject breathes using the maximal 
expiratory flows at any given lung volume in rest conditions. In the case that a 
flow-limited patient needs to increase his or her minute ventilation (for example 
as a result of an effort), he or she will have to breath at larger lung volumes 
since at larger volumes higher flow rates are possible. 
This situation causes an increase in Functional Residual Capacity 
(FRC), and therefore a reduction of Inspiratory Capacity (IC), called dynamic 
hyperinflation. This physiologic condition may be responsible for dyspnoea, 
since patients breaths in a less favourable area of the compliance 
(pressure/volume) curve and requires bigger efforts to achieve similar 
volumetric changes. FL can be evaluated by overlapping the maximal and tidal 
flow/volume curves, and  FL is present if the two curves are superimposed and 
the ventilatory reserve is exhausted.  
In COPD patients, FL has been studied in correlation to dyspnoea (1) 
and as possible determinant of exercise tolerance (2). However, in asthma we 
can make some simple considerations: 
- maximal and tidal flow/volume curves may overlap at the average 
flow level (indices of small airways disease) 
- inflammation, because of the “air trapping” phenomenon, 
correlates with increase in the static volume and then with lung hyperinflation 
- lung hyperinflation may be a consequence  of FL 
FL may be an expression of the small airways dysfunction and may help 
to better characterize the different phenotypes of asthma.  
Based on the above considerations, a subgroup of our patients also 
underwent FL measurement according to the Hyatt technique (maximal and 
tidal flow/volume curves overlapping). Of nineteen asthmatics patients, who 
underwent FL measurement, eight were flow limited at rest. No significant 
differences in FEV1 and other functional parameters, including some small 
airway markers, was observed between flow limited and non flow limited 
patients, with the exception of AaDO2 and aADCO2 that are significantly higher 
 in the flow limited group. In this group a trend towards an increased 
inflammation has also been found (Table 1). Furthermore, flow limited patients 
used more frequently beta2 agonist as needed in comparison with non flow 
limited patients (Table 2). 
These results indicate that the FL can identify a group of asthmatic 
patients with a more severe degree of disease. In fact, this group had a greater 
involvement of small airways (greater impairment of gas exchange), a lower 
disease control (greater beta2 agonist use) and had a greater tendency to 
inflammation. 
Our sample is still too small to draw the final conclusion. It is possible 
that the FL may add useful information that can help to better characterize the 
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Table1. Comparison of the functional and biological parameters between flow limited 
(FL) and no flow limited (NFL) asthmatic patients.  
 FL NFL Sig. 
N° 8 11  
FEV1%(M±SD) 74.25±20.4 89.0±19.7 ns 





CV/VC, %(median) 0.0(0.0 - 17.1) 2.5(0.0 - 25.0) ns 
ΔN2%L-1 (median) 2.7(0.9 - 6.5) 1.6(0.9 - 7.7) ns 
FeNO50ppb (M±SD) 42.5±33.7 38.3±26.9 ns 
CalvNO ppb (M±SD) 9.9±5.1 10.6±6.5 ns 
Sputum eosinophils, %(median) 12.3(7.3 - 62.0) 5.3(0.0 - 34.6) Ns (0.07) 
DAaO2mmHg(M±SD) 34.0±5.8 18.5±8.2* 0.0001 
DaACO2mmHg(M±SD) 5.0±2.1 1.7±2.9* 0.001 
M= mean; SD= standard deviation; FEV1= forced expiratory volume in first second; FEF25-75= 
forced expiratory flow between 25 and 75% of forced vital capacity; ΔN2= the slope of the phase 
III obtained by the single breath nitrogen washout; CV= closing volume; VC= vital capacity; 
CalvNO= alveolar concentration of eNO; A-aDO2 and a-ADCO2= alveolar-arterial and arterial-





Table 2. Comparison of the clinical parameters between flow limited (FL) and no flow 
limited (NFL) asthmatic patients. 
 FL NFL Sig. 
N° 8 11  
 Symptoms/week (M±SD) 4.8±7.6 4.9±10.6 ns 
PEF-MA % (M±SD) 25.8±6.8 18.1±79.8 ns(0.08) 
beta2-use/week (median) 2.0(0.0 - 7.0) 0.0(0.0 – 2.0)* 0.02 
Exacerbations (median) 1.0(0.0 – 3.0) 1.0(0.0 - 2.0) ns 
M= mean; SD= standard deviation; FEV1= forced expiratory volume in the first second; 
PEF-MA= daily maximal amplitude of Peak Expiratory Flow 
  
 
